249 related articles for article (PubMed ID: 33117602)
21. T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.
Bruns M; Wanger J; Schumacher U; Deppert W
Oncotarget; 2016 Oct; 7(40):64543-64559. PubMed ID: 27579535
[TBL] [Abstract][Full Text] [Related]
22. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
Zhu L; Zhao L; Wu M; Chen Z; Li H
Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
[TBL] [Abstract][Full Text] [Related]
23. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
24. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
[TBL] [Abstract][Full Text] [Related]
25. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
26. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu.
Riemer AB; Klinger M; Wagner S; Bernhaus A; Mazzucchelli L; Pehamberger H; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Immunol; 2004 Jul; 173(1):394-401. PubMed ID: 15210798
[TBL] [Abstract][Full Text] [Related]
27. CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models.
Lv Z; Zhang P; Li D; Qin M; Nie L; Wang X; Ai L; Feng Z; Odhiambo WO; Ma Y; Ji Y
Oncoimmunology; 2020; 9(1):1747688. PubMed ID: 32363119
[TBL] [Abstract][Full Text] [Related]
28. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
Maute RL; Gordon SR; Mayer AT; McCracken MN; Natarajan A; Ring NG; Kimura R; Tsai JM; Manglik A; Kruse AC; Gambhir SS; Weissman IL; Ring AM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6506-14. PubMed ID: 26604307
[TBL] [Abstract][Full Text] [Related]
29. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
[TBL] [Abstract][Full Text] [Related]
30. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
31. A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers.
Lin PL; Cheng YM; Wu DW; Huang YJ; Lin HC; Chen CY; Lee H
Cancer Med; 2017 Sep; 6(9):2052-2062. PubMed ID: 28795532
[TBL] [Abstract][Full Text] [Related]
32. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
33. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
34. A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy.
Zeng W; Pan J; Fang Z; Jia J; Zhang R; He M; Zhong H; He J; Yang X; Shi Y; Zhong B; Zeng J; Fu B; Huang M; Liu H
Front Immunol; 2022; 13():925217. PubMed ID: 35795680
[TBL] [Abstract][Full Text] [Related]
35. A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies.
Bu MT; Yuan L; Klee AN; Freeman GJ
Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):202-209. PubMed ID: 35925787
[TBL] [Abstract][Full Text] [Related]
36. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics.
Kotraiah V; Phares TW; Browne CD; Pannucci J; Mansour M; Noe AR; Tucker KD; Christen JM; Reed C; MacKay A; Weir GM; Rajagopalan R; Stanford MM; Chung CS; Ayala A; Huang J; Tsuji M; Gutierrez GM
Front Immunol; 2020; 11():264. PubMed ID: 32210956
[TBL] [Abstract][Full Text] [Related]
37. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.
Wang J; Fei K; Jing H; Wu Z; Wu W; Zhou S; Ni H; Chen B; Xiong Y; Liu Y; Peng B; Yu D; Jiang H; Liu J
MAbs; 2019; 11(8):1443-1451. PubMed ID: 31402780
[TBL] [Abstract][Full Text] [Related]
38. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
[TBL] [Abstract][Full Text] [Related]
39. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
Lin H; Wu Y; Chen J; Huang S; Wang Y
Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
[TBL] [Abstract][Full Text] [Related]
40. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
